Advertisement
ITGR vs LMAT
Which Stock Would AI Choose? Integer Holdings (ITGR) vs. LeMaitre Vascular (LMAT) Stock Comparison
Key Takeaways
- ITGR operates as a contract medical device manufacturer, while LMAT sells branded vascular and cardiac surgical devices directly to hospitals, creating very different business models and growth profiles.
- ITGR agreed to be acquired by private equity firm KKR in a $5.7 billion, $127-per-share transaction, shifting its stock's behavior toward an event-driven, deal-anchored trade.
- LMAT has posted double-digit organic sales growth and raised its full-year guidance, supported by gross margins near 72% and a cash-rich balance sheet.
- ITGR faced margin pressure and a softer 2026 revenue outlook before the acquisition announcement, while LMAT has been in a recent share-price pullback despite improving fundamentals.
- The comparison highlights a contrast between a leveraged, acquisition-driven turnaround story and a self-funded, organic-growth compounder.
Introduction
Investors comparing ITGR and LMAT are effectively weighing two distinct ways to gain exposure to the medical technology supply chain. Both companies serve the cardiovascular space, yet their market positioning, capital structures, and near-term catalysts differ sharply. This stock comparison is most relevant for traders and investors who want to understand how an event-driven acquisition situation (ITGR) measures up against an independent, organically growing specialty device maker (LMAT). By examining relative performance, growth drivers, and risk profiles, readers can better assess which profile aligns with their own objectives and time horizon.
ITGR Overview and Recent Performance
Integer Holdings Corporation is a contract development and manufacturing organization that acts as an outsourced partner to medical device companies, helping them design products and produce components such as batteries, wires, and fully assembled finished devices. Its revenue spans product lines including Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation.
Recent market activity for ITGR has been dominated by an announced acquisition. The company's board initiated a strategic review, and the process culminated in an agreement under which an affiliate of KKR will acquire all outstanding shares for $127 each in a deal valued at roughly $5.7 billion, representing a premium of about 51.8% to its late-April close. Before that announcement, sentiment had cooled as the company reported margin contraction and trimmed its 2026 revenue outlook to a low-single-digit decline. The pending transaction has since anchored the stock near the deal price, reducing its sensitivity to day-to-day operating news.
LMAT Overview and Recent Performance
LeMaitre Vascular, Inc. develops and sells branded devices, implants, and services used in vascular and cardiac surgery, distributing directly to hospitals across global markets. Its niche-oriented product portfolio supports a high-margin, recurring-revenue business model.
In recent quarters, LMAT has delivered double-digit organic sales growth and raised its full-year guidance, with gross margins near 72% and a strong cash position underpinned by roughly $367 million in cash and short-term marketable securities. The company also continues to pay a growing quarterly dividend. Despite these fundamentals, the stock has experienced a notable pullback in recent weeks, and the company announced that its president plans to retire at year-end, introducing a leadership transition to monitor. Analysts generally maintain a Buy consensus, with price targets above the recent share price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems drawn from a broader library of hundreds of AI trading bots that trade thousands of different tickers. Because each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers, only the systems best suited to current market conditions earn a place in this featured section. The robots are designed to scan for patterns, momentum shifts, and volatility signals across markets, providing a data-driven lens for traders evaluating names like ITGR and LMAT. To explore which strategies are currently ranked for this environment, visit the Trending AI Robots page.
Head-to-Head Comparison
The two companies diverge most clearly in their business models. ITGR earns revenue by manufacturing on behalf of larger medical device original equipment manufacturers, which ties its results to customer order patterns and creates operating leverage that can cut both ways. LMAT, by contrast, owns its brands and sells directly to end users, supporting structurally higher gross margins and more direct control over pricing and distribution.
On growth, LMAT has shown stronger recent momentum, with organic sales rising at a double-digit rate and guidance being raised, whereas ITGR guided toward a modest revenue decline amid product-cycle headwinds. Risk profiles also differ: ITGR carries meaningful debt and margin pressure, but its acquisition provides a defined catalyst and floor for near-term price expectations. LMAT holds a clean, cash-heavy balance sheet and a dividend, but faces execution risk around its leadership transition and the challenge of sustaining its premium valuation.
Tickeron AI Verdict
Based on observable factors such as trend consistency, operational stability, catalysts, and relative market positioning, Tickeron's AI would likely view LMAT as the more fundamentally consistent of the two names, given its double-digit organic growth, high margins, robust balance sheet, and rising guidance. At the same time, ITGR offers a distinct, event-driven profile anchored by its pending acquisition, which tends to compress downside volatility relative to the deal price. The assessment is probabilistic rather than definitive: the AI would likely favor LMAT on operational momentum and stability, while recognizing that ITGR's return profile is now largely determined by the completion of the KKR transaction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ITGR is a Hold and LMAT is a Hold.
Momentum Indicator for ITGR turns negative, indicating new downward trend
ITGR saw its Momentum Indicator move below the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned negative. In 66 of the 103 cases, the stock moved further down in the following days. The odds of a decline are at 64%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ITGR moved out of overbought territory on October 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 16 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ITGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ITGR broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where ITGR advanced for three days, in 227 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 162 of 229 cases where ITGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ITGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ITGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.503) is normal, around the industry mean (4.170). P/E Ratio (34.111) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (2.806) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.382) is also within normal values, averaging (40.124).
Momentum Indicator for LMAT turns negative, indicating new downward trend
LMAT saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In 62 of the 104 cases, the stock moved further down in the following days. The odds of a decline are at 60%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for LMAT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 27 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
LMAT moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for LMAT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 229 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 176 of 235 cases where LMAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.783) is normal, around the industry mean (4.946). P/E Ratio (30.528) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ITGR | LMAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 69 | 54 | |
SMR RATING 1..100 | 78 | 52 | |
PRICE GROWTH RATING 1..100 | 38 | 61 | |
P/E GROWTH RATING 1..100 | 22 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LMAT's Valuation (71) in the Medical Specialties industry is in the same range as ITGR (85) in the Electrical Products industry. This means that LMAT’s stock grew similarly to ITGR’s over the last 12 months.
LMAT's Profit vs Risk Rating (54) in the Medical Specialties industry is in the same range as ITGR (69) in the Electrical Products industry. This means that LMAT’s stock grew similarly to ITGR’s over the last 12 months.
LMAT's SMR Rating (52) in the Medical Specialties industry is in the same range as ITGR (78) in the Electrical Products industry. This means that LMAT’s stock grew similarly to ITGR’s over the last 12 months.
ITGR's Price Growth Rating (38) in the Electrical Products industry is in the same range as LMAT (61) in the Medical Specialties industry. This means that ITGR’s stock grew similarly to LMAT’s over the last 12 months.
ITGR's P/E Growth Rating (22) in the Electrical Products industry is somewhat better than the same rating for LMAT (82) in the Medical Specialties industry. This means that ITGR’s stock grew somewhat faster than LMAT’s over the last 12 months.
| ITGR | LMAT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | N/A |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 60% |
| MACD ODDS (%) | N/A | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 68% |
| Advances ODDS (%) | 21 days ago 67% | 14 days ago 68% |
| Declines ODDS (%) | 7 days ago 63% | 8 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 51% | N/A |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ITGR’s FA Score shows that 1 FA rating(s) are green while LMAT’s FA Score has 0 green FA rating(s).
- ITGR’s FA Score: 1 green, 4 red.
- LMAT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ITGR’s TA Score shows that 3 TA indicator(s) are bullish while LMAT’s TA Score has 4 bullish TA indicator(s).
- ITGR’s TA Score: 3 bullish, 4 bearish.
- LMAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
ITGR (@Medical/Nursing Services) experienced а -0.15% price change this week, while LMAT (@Pharmaceuticals: Other) price change was -3.81% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.95%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was -1.38%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.49%. For the same industry, the average monthly price growth was +1.99%, and the average quarterly price growth was +15.86%.
Reported Earning Dates
ITGR is expected to report earnings on Feb 18, 2027.
LMAT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (+1.95% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+3.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ITGR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ITGR has been loosely correlated with RDNT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ITGR jumps, then RDNT could also see price increases.
| Ticker / NAME | Correlation To ITGR | 1D Price Change % | ||
|---|---|---|---|---|
| ITGR | 100% | N/A | ||
| RDNT - ITGR | 50% Loosely correlated | +0.11% | ||
| TWST - ITGR | 50% Loosely correlated | +8.73% | ||
| A - ITGR | 48% Loosely correlated | +2.02% | ||
| IQV - ITGR | 48% Loosely correlated | +1.61% | ||
| ICUI - ITGR | 46% Loosely correlated | -0.34% | ||
More | ||||